Previous trials of anti-VEGFR agent combinations for SCLC typically excluded patients with large vessel invasion or high bleeding risk.17,18 This exclusion poses a challenge to the clinical application or optimization of anti-angiogenic combination strategies in this subset of ES-SCLC patients. Here, KDR is linked to small cell lung carcinoma.